Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX9930 in Paroxysmal Nocturnal Hemoglobinuria
NCT05741346Phase 2Terminated
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of vimircopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by BioCryst Pharmaceuticals, Inc.. Started Jan 2023; status: terminated.
02
Drugs
vimircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05741346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05741346.